Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Non-Current Liabilities (2024 - 2025)

Corvus Pharmaceuticals has reported Other Non-Current Liabilities over the past 2 years, most recently at $3.8 million for Q1 2025.

  • Quarterly results put Other Non-Current Liabilities at $3.8 million for Q1 2025, changed N/A from a year ago — trailing twelve months through Mar 2025 was $3.8 million (changed N/A YoY), and the annual figure for FY2024 was $28.9 million, changed.
  • Other Non-Current Liabilities for Q1 2025 was $3.8 million at Corvus Pharmaceuticals, down from $28.9 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for CRVS hit a ceiling of $40.0 million in Q3 2024 and a floor of $3.8 million in Q1 2025.